Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false positives, reduce the number of scans and improve patient outcomes. Cizzle has converted a memorandum of understanding (MoU) with partners in China into a full strategic alliance for the development and commercialisation of its lung cancer test in China.
08 Feb 2022
Cizzle Biotechnology (CIZ) Strategic alliance in China
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Cizzle Biotechnology (CIZ) Strategic alliance in China
Cizzle Biotechnology Holdings PLC (E7F0:FRA) | 0 0 0.0%
- Published:
08 Feb 2022 -
Author:
Martin Hall -
Pages:
6
Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false positives, reduce the number of scans and improve patient outcomes. Cizzle has converted a memorandum of understanding (MoU) with partners in China into a full strategic alliance for the development and commercialisation of its lung cancer test in China.